glp-1 heart rate increase Differential effects of glucagon-like peptide-1 receptor agonists on | Cardiovascular Diabetology Cardiovascular Protective Properties of GLP-1

Ahluwalia, M

Novo Nordisk announced FDA acceptance of their New Drug Application (NDA) for a 25 mg oral version of Wegovy for two new indications: (1) chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition, and (2) to reduce the risk of major adverse cardiac events (MACE) in adults with overweight or obesity and established CVD

M.QinJ.CarrollM

These weight management supplements often have additional ingredients like caffeine, garcinia cambogia, and chromium to effectively boost metabolism, and energy and even enhance focus

Studies that have included larger proportions of patients with CKD are few, and the observations on cardiovascular outcomes have been mixed

By the end, youll have an essential toolkit of science-supported, low- to zero-cost focus and concentration strategies to select from that can be tailored to your physical and mental performance needs